Cisplatin-Based Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer: Is It Feasible?
Clément Dumont 1, Madeleine Lefèvre 2, Quiterie Aussedat 1, Pierre-Louis Reignier 3, Alexandra Masson-Lecomte 3, Evanguelos Xylinas 4, Hélène Gauthier 1, Virginie Fossey-Diaz 2, Amélie Arégui 2, Stéphane Culine 1,2,*
Medical oncology department, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France
Oncogeriatry unit, AP-HP.Nord - Université de Paris, Paris, France
Urology department, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France
Urology department, Bichat Hospital, AP-HP.Nord - Université de Paris, Paris, France
Academic Editor: Michael Fossel
Special Issue: Bladder Cancer in Older Adults
Received: July 23, 2021 | Accepted: October 27, 2021 | Published: November 08, 2021
OBM Geriatrics 2021, Volume 5, Issue 4, doi:10.21926/obm.geriatr.2104183
Recommended citation: Dumont C, Lefèvre M, Aussedat Q, Reignier PL, Masson-Lecomte A, Xylinas E, Gauthier H, Fossey-Diaz V, Arégui A, Culine S. Cisplatin-Based Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer: Is It Feasible?. OBM Geriatrics 2021; 5(4): 183; doi:10.21926/obm.geriatr.2104183.
© 2021 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.
Muscle-invasive bladder cancer (MIBC) is associated with early metastasis and high mortality, leading to a poor prognosis. Radical cystectomy (RC) remains the gold standard local treatment for non-metastatic MIBC; however, it has been observed that many patients die of distant metastases within two years of RC, suggesting the presence of micro-metastases at the time of surgery [1,2]. In past decades, the delivery of perioperative chemotherapy before (neoadjuvant) or after (adjuvant) RC was utilized for treating micro-metastases, thereby increasing overall survival. However, presently, only cisplatin-based neoadjuvant combination chemotherapy regimens (C-NAC) are being utilized as it has an absolute benefit of 5% on overall survival with Level I evidence in international guidelines [3,4,5].
Outcome data on elderly patients treated with C-NAC are limited in both clinical trials and retrospective series. Results of subgroup analyses in prospective trials indicate that C-NAC is beneficial for patients ≥ 65 years. However, several studies have reported the underutilization of C-NAC in real life, which may be due to factors like toxicity concerns, increased perioperative complications, etc., as well as higher comorbidity scores in elderly patients as primary factors associated with lower use of C-NAC [6,7,8]. In the present report, we assessed the feasibility of C-NAC in a cohort of 51 consecutive patients aged 75 years or above who were treated at our institution in the last decade.
2. Patients and Methods
2.1 Patient Identification and Data Retrieval
In order to identify the patients, we screened our database from January 2011 to March 2020. These patients were treated at our institution with at least one cycle of C-NAC for histologically proven pure or predominant urothelial MIBC and evidence of cT2-4a, cN0-N3, and M0 disease. In this study, patients with non-muscle-infiltrating disease, inoperable locally advanced disease, and non-urothelial bladder cancer were excluded.
2.2 Treatment Plan
Two chemotherapy regimens were used: Gemcitabine/cisplatin (GC) and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC). The standard doses of GC were gemcitabine 1250 mg/m2 on days one and eight and cisplatin 70 mg/m2 on day one every three weeks. The dosage of dd-MVAC included methotrexate 30 mg/m² on day one, vinblastine 3 mg/m² on day two, doxorubicin 30 mg/m² on day two, and cisplatin 70 mg/m² on day two every 14 days. Both regimens were delivered in an inpatient setting, and all patients received granulocyte-colony stimulating factor (G-CSF). The type of regimen, as well as dose reductions, were at the discretion of the treating physician. The planned number of cycles was four for GC and six for dd-MVAC; however, in case of excessive toxicity or disease progression, chemotherapy could be discontinued prematurely at the discretion of the treating physician. At the end of chemotherapy, further treatments were decided according to a multidisciplinary approach and patients’ preference (RC and lymphadenectomy, pelvic chemoradiotherapy, or surveillance).
2.3 Safety Assessment
Clinical toxicities and significant laboratory values were documented at the beginning of each chemotherapy cycle. Toxicities were retrospectively graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0), based on individual medical reports. Reasons for changes in the planned chemotherapy cycles were notified.
From May 2012 to March 2020, 51 patients aged 75 to 90, with a median age of 79 years, received C-NAC (dd-MVAC: 38; GC: 13). Twenty (39%) patients were older than 80 years; out of them, six patients were above the age of 85. Age distribution according to the chemotherapy regimen is shown in Figure 1. Initial characteristics of the patient population indicated that they were suitable candidates for C-NAC, with good performance status and adequate renal function (Table 1).
Figure 1 Age distribution of patients according to the chemotherapy regimen.
3.2 Treatment Delivery
Two patients received reduced cisplatin doses at the first cycle because of impaired renal function. The median number of cycles was four for both regimens. Eighteen (47%) patients treated with dd-MVAC received more than four cycles of chemotherapy. Overall feasibility of a complete 4-cycle chemotherapy course was 75%, regardless of the chemotherapy regimen (dd-MVAC: 76%; GC: 69%). No differences were observed in the completeness of chemotherapy between patients aged 75 to 79 and patients aged 80 to 84 (Figure 2). The feasibility of chemotherapy seemed to drop in patients aged 85 or above; however, it should be noted that the number of patients was small in this subset. Dose reductions were done in 57% of the patients (dd-MVAC: 55%; GC:62%). Thirteen (25%) patients discontinued chemotherapy before the fourth cycle, and the reasons included toxicity in ten patients, planned surgery in one patient, COVID-19 infection in one patient, and death from an unknown cause (sudden death) in one patient. Toxicities responsible for chemotherapy discontinuation, possibly multiple, were renal in five patients, hematological in four patients, infectious in two patients, and general in two patients. One patient discontinued dd-MVAC because of nephrotoxicity and pursued chemotherapy with carboplatin and gemcitabine.
Figure 2 Completeness of chemotherapy in patients according to age groups (digits indicate the number of patients).
At the end of C-NAC, 27 patients underwent surgery, 12 patients were treated with chemoradiotherapy, and three patients underwent active surveillance. Other six patients did not receive any locoregional treatment (the reason was disease progression in one patient). Details on post-chemotherapy locoregional management were unavailable for two patients.
All patients experienced at least one adverse event from C-NAC. Overall, grade 3-4 adverse events were noted in 57% of patients, mostly due to hematological toxicity. Red blood cell transfusion was performed in 29% of patients, and 8% underwent platelet transfusion. The incidence of febrile neutropenia was 6%. Grade 5 adverse event occurred in only one patient aged 79, who died from an unknown cause shortly after a single dd-MVAC cycle. When considering only the first four chemotherapy cycles in all patients (i.e., disregarding toxicity from cycles five and six in dd-MVAC patients), the incidence of grade 3-4 adverse events dropped to 47%. Adverse events according to chemotherapy regimens are detailed in Table 2. Grade 3-4 adverse events were significantly more common with dd-MVAC than with GC (68% vs. 23%; p = 0.008).
Bladder cancer is an age-associated malignancy, with the median age at diagnosis being 73 years. More than 30% of new cases are observed in patients aged 75 or above. The age-related decline in performance status and increase in comorbidities significantly affect the risk of treatment-related toxicities; therefore, elderly patients are less likely to receive standard of care treatments, thereby making them prone to undertreatments .
Presently, the standard of care for patients with MIBC is a combination of C-NAC and RC. Any deviation in the delivery of these treatments jeopardizes the chances of cure. However, a well-known important limitation to the use of C-NAC is cisplatin itself, since adequate renal, cardiovascular, and hearing functions, as well as the absence of neuropathy, are required for an optimal delivery . In addition, compliance with contraindications is likely to exclude up to 50% of patients from undergoing C-NAC, particularly in older populations. Despite all these limitations, cisplatin is the most active cytotoxic agent against MIBC. .
Retrospective studies have clearly shown that C-NAC is underutilized worldwide, although recent surveys indicate an increase in its application since 2010 [12,13]. The potential clinical reasons contributing to the underutilization of C-NAC in elderly patients include older age as well as higher comorbidity scores [6,7,8]. Based on a national database from the United States and Porto-Rico, Carvalho et al. reported that only 18.8% of patients aged ≥ 75 received C-NAC. Of the 81.2% of patients who did not receive C-NAC, only 2.5% were ineligible due to true contraindication. In addition, 68% of patients did not receive C-NAC simply because it was not planned, implying that this treatment option may not even be offered or discussed by some providers after the initial diagnosis of MIBC .
Renal function, in particular, is often compromised in older patients with MIBC due to smoking, comorbidities, and/or obstructive nephropathy. Given the potential for renal toxicity with cisplatin-based chemotherapy, adequate renal function is a prerequisite for C-NAC. Clinical trials and medical oncologist community surveys have arrived at the common eligibility threshold of measured or calculated creatinine clearance (CrCl) of ≥ 60 mL/min . However, no robust data exist to support a specific renal function threshold and an optimal methodology to assess the eligibility of patients for receiving the treatment as well as dose adaptations of cisplatin throughout C-NAC in MIBC. To overcome this, an algorithm that eliminates an absolute CrCl threshold and emphasizes a multidisciplinary, patient-centered approach was recently proposed .
Results of this study indicate that chronologic age itself should not directly affect treatment options. In a selected population of elderly patients with no standard contraindication for cisplatin, overall feasibility of 75% was achieved, when considering a 4-cycle chemotherapy course (regardless of the chemotherapy regimen). More serious adverse events were observed in patients who received dd-MVAC, mainly because of its higher hematological toxicity. Also, the 6% febrile neutropenia rate was similar to those described in pivotal studies with younger patients, and only 8% of the patients needed a platelet transfusion. No toxic death was observed, although one patient died from an unknown cause shortly after a single dd-MVAC cycle. However, the optimal modalities for C-NAC, including the number of cycles as well as the quality of drugs combined with cisplatin, remain a matter of debate. In a French randomized trial comparing four cycles of GC to six cycles of dd-MVAC, the local control rate was greater in the dd-MVAC arm, but the potential impact on survival is still unknown .
The first limitation of our study is linked to its retrospective nature, as the incidence of adverse events could be underestimated. Second, we did not incorporate a formal geriatric assessment as a routine in the clinical evaluation of our patients prior to the decision to undertake chemotherapy. Although a clear selection was made regarding the contraindications to cisplatin, the implementation of routine use of geriatric assessment tools may have potentially allowed for a better selection of vulnerable patients. Finally, we did not report outcome data. However, several studies indicate that in elderly patients with MIBC deemed suitable for C-NAC, survival and other outcomes were similar to that of their younger counterparts [16,17].
In conclusion, C-NAC is a feasible treatment approach even in elderly patients without any contraindication to cisplatin. A coordinated multidisciplinary approach, including a geriatric oncologist, may help to identify patients at increased risk for chemotherapy-induced toxicity and, therefore, optimize the use of NAC in older patients with MIBC .
Conception and design: Clément Dumont, Stéphane Culine. Provision of study materials or patients: Clément Dumont, Madeleine Lefèvre, Alexandra Masson-Lecomte, Evanguelos Xylinas, Hélène Gauthier, Virginie Fossey-Diaz, Amélie Aregui. Collection and assembly of data: Clément Dumont, Quiterie Aussédat, Pierre-Louis Régnier. Data analysis and interpretation: Clément Dumont, Stéphane Culine. Manuscript writing: Clément Dumont, Stéphane Culine. Final approval of manuscript: all authors.
The authors state they have no conflict of interest.
- Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Skinner SB, et al. Radical cystectomy in the treatment of invasive bladder cancer. Long-term results in 1054 patients. J Clin Oncol. 2001; 19: 666-675. [CrossRef]
- Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the bladder cancer research consortium. J Urol. 2006; 176: 2414-2422. [CrossRef]
- Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866. [CrossRef]
- Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer(ABC) meta-analysis collaboration. Eur Urol. 2005; 48: 202-205. [CrossRef]
- International collaboration of trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-2177. [CrossRef]
- Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, et al. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. Can Urol Assoc J. 2016; 10: E82-E86. [CrossRef]
- Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, et al. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2019; 13: 24-28. [CrossRef]
- Carvalho FL, Zeymo A, Egan J, Kelly CH, Zheng C, Lynch JH, et al. Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. Investig Clin Urol. 2020; 61: 390-396. [CrossRef]
- Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, et al. Bladder cancer in the elderly patient: Challenges and solutions. Clin Interv Aging. 2015; 10: 939-949. [CrossRef]
- Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011; 12: 211-214. [CrossRef]
- Mottet N, Ribal MJ, Boyle H, de Santis M, Caillet P, Choudhury A, et al. Management of bladder cancer in older patients: Position paper of a SIOG task force. J Geriatr Oncol. 2020; 11: 1043-1053. [CrossRef]
- Anan G, Hatakeyama S, Fujita N, Iwamura H, Tanaka T, Yamamoto H, et al. Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: A multicenter study. Oncotarget. 2017; 8: 86130-86142. [CrossRef]
- Booth CM, Karim S, Brennan K, Siemens DR, Peng Y, Mackillop WJ. Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? Urol Oncol. 2018; 36: 89.e13-89.e20. [CrossRef]
- Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, et al. Defining cisplatin eligibilityin patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021; 18: 104-114. [CrossRef]
- Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, et al. Randomized phase III of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Analysis of the GETUG/AFU V05 VESPER trial secondary end-points: Chemotherapy toxicity and pathological responses. Eur Urol. 2021; 79: 214-221. [CrossRef]
- Chau C, Wheater M, Geldart T, Crabb SJ. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. Eur J Cancer Care. 2015; 24: 155-162. [CrossRef]
- Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, et al. Neoadjuvant chemotherapy in elderly patients with bladder cancer: Oncologic outcomes from a single institution experience. Clin Genitourinary Cancer. 2017; 15: e583-e589. [CrossRef]